Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Compass Pathways
Biotech
Why other Big Pharmas could follow Lilly into psychedelics
Industry experts told Fierce that Eli Lilly's $2.8 billion acquisition of AtaiBeckley should give the psychedelics space added momentum.
Will Maddox
,
Darren Incorvaia
Jul 20, 2026 4:00am
‘Real momentum’ or ‘absurd’? Trump stance shakes up psychedelics
May 4, 2026 3:30am
Compass, Usona and Transcend score priority vouchers amid psychedelic push
Apr 24, 2026 3:51pm
Compass guides psychedelic to 2nd pivotal depression win
Feb 17, 2026 8:39am
Compass' psychedelic therapy wins ph. 3, investors unimpressed
Jun 23, 2025 8:05am
Compass delays phase 3 psychedelic data, lays off 30% of staff
Oct 31, 2024 9:00am
